Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P49441

UPID:
INPP_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P49441

BACKGROUND:
Inositol polyphosphate 1-phosphatase, with the unique identifier P49441, is a Mg(2+)-dependent enzyme essential for the inositol phosphate metabolism pathway. It specifically hydrolyzes the phosphate at the 1-position of inositol 1,4-bisphosphate and inositol 1,3,4-trisphosphate, playing a pivotal role in the regulation of intracellular signaling molecules.

THERAPEUTIC SIGNIFICANCE:
The exploration of Inositol polyphosphate 1-phosphatase's function offers a fertile ground for identifying novel therapeutic approaches. Given its central role in the regulation of key signaling molecules, targeting this enzyme could lead to the development of innovative treatments for diseases where cellular signaling is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.